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a b s t r a c t 
An ideal cell source for human therapeutic and disease modeling applications should be easily accessi- 
ble and possess unlimited differentiation and expansion potential. Human induced pluripotent stem cells 
(hiPSCs) derived from peripheral blood mononuclear cells (PBMCs) represent a promising source given 
their ease of harvest and their pluripotent nature. Previous studies have demonstrated the feasibility 
of using PBMC-derived hiPSCs for vascular tissue engineering. However, so far, no endothelialization of 
hiPSC-derived tissue engineered vascular grafts (TEVGs) based on fully biodegradable polymers without 
xenogenic matrix components has been shown. 
In this study, we have generated hiPSCs from PBMCs and differentiated them into αSMA- and calponin- 
positive smooth muscle cells (SMCs) as well as endothelial cells (ECs) positive for CD31, vWF and eNOS. 
Both cell types were co-seeded on PGA-P4HB starter matrices and cultured under static or dynamic con- 
ditions to induce tissue formation in vitro . The resulting small diameter vascular grafts showed abundant 
amounts of extracellular matrix, containing a thin luminal layer of vWF-positive cells and a subendothe- 
lial αSMA-positive layer approximating the architecture of native vessels. Our results demonstrate the 
successful generation of TEVGs based on SMCs and ECs differentiated from PBMC-derived hiPSC com- 
bined with a biodegradable polymer. These results pave the way for developing autologous PBMC-derived 
hiPSC-based vascular constructs for therapeutic applications or disease modeling. 
Statement of Signiﬁcance 
We report for the ﬁrst time the possibility to employ human peripheral blood mononuclear cell (PBMC)- 
derived iPSCs to generate biodegradable polymer-based tissue engineered vascular grafts (TEVG), which 
mimic the native layered architecture of blood vessels. 
hiPSCs from PBMCs were differentiated into smooth muscle cells as well as endothelial cells. These cells 
were co-seeded on a biodegradable PGA/P4HB scaffold and cultured in a bioreactor to induce tissue for- 
mation in vitro . The resulting small diameter TEVG showed abundant amounts of extracellular matrix, 
containing a αSMA-positive layer in the interstitium and a thin luminal layer of vWF-positive endothelial 
cells approximating the architecture of native vessels. 
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Our ﬁndings improving the generation of autologous vascular replacements using blood as an easily ac- 
cessible cell source. 
© 2019 Acta Materialia Inc. Published by Elsevier Ltd. 
This is an open access article under the CC BY-NC-ND license. 
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1. Introduction 
Cardiovascular disease remains the leading cause of morbid- 
ity and mortality, accounting for more than 17 million deaths per 
year worldwide [1] . Replacement of affected vascular tissues has 
been widely used to treat structural cardiovascular disease such 
as coronary heart disease, aortic aneurysm and peripheral vas- 
cular disease [2] . However, successful treatment is often limited 
by the lack of suitable autologous replacement tissues. So far, ex- 
panded polytetraﬂuoroethylene (ePTFE), polyethylene terephthalate 
(PET) and polyurethane (PU) have been successfully used to pro- 
duce synthetic vascular grafts with a diameter greater than 6 mm 
[3,4] . Grafts smaller than 6 mm in diameter lead to many com- 
plications including acute thrombosis and stenosis caused by the 
lack of functional endothelium coverage [5] . Several approaches 
focusing on the prevention of thrombogenicity of these synthetic 
materials have been undertaken; in particular, coating of the lu- 
minal surface with heparin and other anticoagulant materials has 
been attempted – however, with limited success [6,7] . In addition, 
these grafts do not show growth-adaptive behavior, which would 
be of particular importance in children that require multiple re- 
operations due to the lack of growth potential [8] . Therefore, the 
current synthetic vascular replacements are suboptimal and tis- 
sue engineering (TE) is proposed as a solution by replacing tis- 
sues or organs with functional autologous replacement constructs. 
Tissue-engineered vascular grafts (TEVGs) represent living vascu- 
lar replacement constructs, where vascular cells are seeded onto a 
three-dimensional biodegradable scaffold and then stimulated via 
conditioning in a bioreactor to promote tissue formation in vitro . 
However, mature vascular cells are associated with limited access, 
expansion and differentiation potential [9] . In general, the source 
of vascular cells represents a central problem for cell-based vascu- 
lar therapies as isolated vascular cells from donor tissues are lim- 
ited in availability and quantity. Moreover they show limited pro- 
liferation, extra cellular matrix (ECM) formation capacity, and cel- 
lular functionality following the extensive in vitro expansion pro- 
cess [10] . Therefore, in recent years different cell sources have been 
tested also with a focus on their use for vascular tissue engineer- 
ing [11,12] . Smooth muscle cells (SMCs) can be differentiated out of 
alternative cell sources such as bone-marrow mesenchymal stem 
cells [13,14] , endothelial progenitor cells [15] , or adipose-derived 
stem cells [16] . Nonetheless, the proliferation and differentiation 
capabilities of adult stem cells considerably decline with aging 
donors [17] and strongly depends on the tissue source cells are 
harvested [18] . An interesting alternative is the use of the so-called 
human induced pluripotent stem cells (hiPSCs). hiPSCs share simi- 
lar proliferation capacity, differentiation potential and gene expres- 
sion with embryonic stem cells (ESCs) and are able to differen- 
tiate into any cell type of the human body. Furthermore, hiPSCs 
can be generated from potentially any terminally differentiated cell 
[19] providing an unlimited source of proliferating cells and over- 
coming therefore the limitations of conﬁned donor cell availability 
as well as limited proliferation capacity. Thus, the use of hiPSCs for 
tissue engineering may represent an ideal cell source and therefore 
the possibility to reprogram somatic cells from a patient and gen- 
erate ‘customized’ tissues from only few cells has created substan- 
tial hope. 
Since the ﬁrst iPSCs were generated from skin ﬁbroblasts, many 
other sources of adult somatic cells have been tested for their suit- 
ability for reprogramming [19] . For instance, the generation of hiP- 
SCs from peripheral blood mononuclear cells (PBMCs) has many 
beneﬁts, such as their ease of harvest or direct reprogramming of 
harvested cells without in vitro propagation. 
Therefore, the present study aims at the generation of TEVGs 
based on SMCs and endothelial cells (ECs) differentiated from 
PBMC-derived hiPSCs combined with a fully biodegradable poly- 
mer matrix based on PGA and P4HB. These results pave the way 
for developing autologous vascular replacements, as well as a basis 
for modeling human disease in vitro using blood as the only, easily 
accessible, cell source. 
2. Materials and methods 
2.1. Isolation and reprogramming of PBMC 
Human peripheral blood was collected with written informed 
consent according to the permission from the cantonal ethics 
commission of Zurich, Switzerland [KEK-ZH-2014-0430]. PBMCs 
were isolated according to standard protocols using the Ficoll- 
Paque method. The reprogramming of PBMCs into hiPSCs was 
induced according to previously reported protocol [20] . Shortly, 
PBMCs reprogramming was achieved using viral vectors, which 
lead to the simultaneous expression of the speciﬁc transcription 
factors OCT4, SOX2, c-MYC and KLF4 (STEMCCA lentiviral vec- 
tor, Boston University School of Medicine, Boston, USA). The in- 
fected cells were then seeded on mitotically inactivated mouse em- 
bryonic ﬁbroblasts (MEFs) and cultured in human iPSCs medium 
(DMEM/F12 (Invitrogen, Switzerland), 20% Knockout serum re- 
placement (Invitrogen, Switzerland), 100 mM nonessential amino 
acids (Sigma, Switzerland), 50 mM 2-mercaptoethanol (Life Tech- 
nologies, Switzerland), 1 mM l -glutamine (Sigma, Switzerland), 
50 U/ml penicillin/streptomycin (Sigma, Switzerland), 10 ng/ml ba- 
sic ﬁbroblast growth factor (bFGF) (Life Technologies, Switzer- 
land)). The reprogramming process took about 15–30 days and ﬁ- 
nally, embryonic stem like colonies were picked and expanded. 
2.2. Characterization of PBMC-derived hiPSCs 
Three different hiPSC lines (IREMi001A, IREMi001B, IREMi001C) 
were characterized using a standard series of quality controls as 
follows: 
• Quantitative Real-Time PCR (qRT-PCR): Total RNA was ex- 
tracted using RNeasy Mini Kits (Qiagen, Switzerland) and re- 
verse transcription was carried out using Superscript III RT (In- 
vitrogen, Switzerland) according to the manufacturer‘s instruc- 
tions. qRT-PCR were performed using Rotor-Gene SYBR Green 
PCR Kit SYBR (Qiagen, Switzerland) and primers for Oct4, Sox2, 
Nanog, Rex1, and Dppa3 (Microsynth, Switzerland). Reactions 
were run in triplicates and using standard conditions on a 
Rotor-Gene Q (Qiagen, Switzerland). All primers are listed in 
Supplemental Table 1. 
• Alkaline Phosphatase (AP) activity: Cells were ﬁxed with 4% 
paraformaldehyde (Sigma-Aldrich, Switzerland), washed with 
PBS and later with alkaline buffer for 10 min. Then alkaline 
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phosphatase solution (10 ml alkaline buffer containing 45 μl 
NBT and 35 μl BCP) was added and the reaction was stopped 
with TRIS-EDTA for 15 s. Staining were analyzed with DMIL LED 
ﬂuorescence microscope (Leica, Germany) and the Leica soft- 
ware (Leica, Germany). 
• Immunoﬂuorescence : hiPSCs were cultured on a 3.5 cm dish, 
ﬁxed with 4% paraformaldehyde, and incubated over night at 
4 °C with primary antibodies (Supplemental Table 2). Secondary 
antibodies were incubated for 1 h (Supplemental Table 2) and 
picture were taken and analyzed with DMIL LED ﬂuorescence 
microscope and the Leica software. 
• In vitro embryoid body formation : hiPSCs were cultured in 
suspension in hiPSC medium without bFGF to form embryoid 
bodies (EB). After 3 weeks EB were harvested and RNA isolated 
for gene expression or plated for further differentiation. 
• Karyotyping : hiPSCs were arrested in metaphase by treatment 
with 80 ng/ml colcemid for 1 h. Then harvested and treated 
with hypotonic solution (0.075 M KCl), followed addition of 
ﬁx solution (MeOH 3:1 Acetic Acid). Metaphases spreads were 
stained by Quinacrine (Sigma). Images were taken on a Zeiss 
Axioskop HBO 50 ﬂuorescent microscope (Zeiss) and arranged 
in Ikaros Software (MetaSystems). 
• Teratoma assay: 2 ×10 5 undifferentiated, MEF free hiP- 
SCs were injected subcutaneously into one dorsal ﬂank of 
NOD.CB17-Prkdc scid mice. 10–12 weeks later teratomas were 
microscopically (histology) analysed. The veterinary oﬃce of 
the Canton Zurich, Switzerland approved all animal experi- 
ments (ZH-171/2014). 
2.3. Differentiation of hiPSCs 
hiPSC were separated from MEFs and cultured in suspension 
for 7 days in ultra-low attachment dishes (Corning, USA) in hiPSC 
medium without bFGF to form EBs, which were then plated for 
further differentiation into SMCs and ECs 
2.3.1. Smooth muscle cells 
For muscle differentiation, attached EBs were cultured in high 
glucose DMEM (Sigma, Switzerland), 10% FBS (Sigma, Switzer- 
land), 5% horse serum (Life Technologies, Switzerland), 100 mM 
nonessential amino acids, 100 mM 2-mercaptoethanol, 1 mM l - 
glutamine, 50 U/ml penicillin/streptomycin. After 14 days medium 
was changed to Smooth Muscle Growth Medium-2 (SmGM-2) 
(Lonza, Switzerland) and further cultured for 14 days. All differen- 
tiated cells were ﬁxed for immunoﬂuorescence or ﬂow cytometric 
analysis (see 2.4), lysed for total RNA extraction or further cultured 
for TE (antibodies and primers are listed in Supplemental Tables 
1 and 2). As a positive control primary human aortic SMCs were 
commercially obtained (CC-2571; Lonza, Switzerland). 
2.3.2. Endothelial cells 
The differentiation of hiPSCs into ECs was induced according to 
previously reported protocol with some modiﬁcations [21] . Brieﬂy, 
hiPSCs were cultured in suspension for 10 days in a medium 
consisting of DMEM, 20% FBS, 2 mM l -glutamine, 100 μM 2- 
mercaptoethanol, 100 μM NEAA, 50 ng/ml ascorbic acid, 125 U/ml 
penicillin, 125 mg/ml streptomycin. EBs were dissociated into sin- 
gle cells with 2 mg/ml collagenase B (Roche, Switzerland) for 2 h 
then Cell Dissociation Buffer (Invitrogen, Switzerland) for 15 min 
at 37 °C shaking at 1100 rpm. VE-cadherin+ cells were isolated 
by magnetic bead sorting (Miltenyi Biotec, USA). Isolated hiPSC- 
derived ECs were plated at 20,0 0 0 cells/cm 2 on ﬁbronectin coated 
dishes (Corning, USA) in endothelial cell medium (EGM-2; Lonza, 
Switzerland). All differentiated cells were either ﬁxed for im- 
munoﬂuorescence or ﬂow cytometric analysis (see 2.4), or lysed 
for total RNA extraction or further cultured for TE (antibodies and 
primers are listed in Supplemental Tables 1 and 2). Moreover, as a 
positive control ECs were isolated from human umbilical cord with 
informed consent according to the cantonal ethics commission of 
Zurich, Switzerland [KEK-ZH-20 09-0 095]. 
2.4. Flow cytometric analysis 
For the purpose of nuclear transcription factor staining, the 
cells were washed with PBS, ﬁxed in 1% paraformaldehyde ( Elec- 
tron Microscopy Sciences , USA), for 20 min at RT and permeabilized 
by FACS buffer and 0.5% Saponin (Sigma-Aldrich, Switzerland) for 
20 min at 4 °C. Incubation with directly labeled αSMC antibody was 
carried out at 4 °C for 25 min, followed by 3 washes. For the pur- 
pose of surface antigen staining, the cells were washed with PBS, 
incubated with the directly labeled CD31 antibody for 20 min at 
4 °C and subsequently washed. The antibodies listed in Supplemen- 
tary Table 2. Cells were acquired using a LSR Fortessa (BD Bio- 
science, USA) and the data sets were analyzed by FlowJo software 
(Tree Star, Inc., USA). 
2.5. Tissue engineering 
2.5.1. Surface morphology of biomaterials 
Samples were mounted on electron imagining stubs using car- 
bon tape and a ﬁeld emitting electron microscope used to im- 
age samples at 15 kV power (Zeiss, FESEM Ultra Plus) for clar- 
ity. For each sample, four regions of interest (ROI) measuring 
10 0 0 ×800 μm were imaged from which ﬁve ﬁbers per ROI were 
measured using Image J software (NIH, v1.48s, line tool) to deter- 
mine the average ﬁber diameter of an ROI. For scaffold porosity, an 
additional four ROIs measuring 30 0 0 ×2250 μm were imaged. Each 
porosity ROI image was then automatically thresholded in Image J 
and porosity was deﬁned as the percent area that was non-ﬁber 
(ie empty/porous space). 
2.5.2. Scaffold fabrication 
Vessels were fabricated from non-woven polyglycolic acid (PGA) 
meshes (thickness 0.5 mm; speciﬁc gravity 70 mg/cm 3 ; Cellon, Lux- 
embourg) and coated with 1.75% poly-4-hydroxybutyrate (P4HB; 
TEPHA, Inc., USA) by dipping into a tetrahydrofuran (THF) solu- 
tion (Sigma-Aldrich, Switzerland). After solvent evaporation and 
vacuum drying overnight, the scaffolds were placed into a 70% 
EtOH (Sigma-Aldrich, Switzerland) for 30 min to obtain sterility, 
followed by two washing cycles with PBS (Sigma-Aldrich, Switzer- 
land). Thereafter, scaffolds were pre-incubated in SmGM-2 with 
supplements for 12–24 h to facilitate cell attachment. 
2.5.3. Cell seeding 
hiPSCs-derived SMCs were seeded onto tubular scaffolds (length 
1 cm and inner diameter 0.7 mm) using 1.0 ∗10 6 cells/cm 2 . Fibrino- 
gen (Sigma-Aldrich, Switzerland) (10 mg/mL of active protein) and 
thrombin (Sigma-Aldrich, Switzerland) were prepared, used and 
titrated to an optimal clotting time of approximately 30 s by adapt- 
ing the concentration of ﬁbrinogen. The cells were resuspended 
in a ﬁbrinogen-thrombin co-solution and evenly seeded into the 
inner lumen and onto the outer layer. After static incubation 
of seeded constructs in SmGM-2 (with supplements and 0.9 mM 
of l -ascorbic acid-2-phosphate (Sigma-Aldrich, Switzerland)) for 
7 days, they were either placed into a bioreactor under pulsatile 
ﬂow for additional mechanical stimulation via shear stress (dy- 
namic condition) or kept under static conditions. The pulsatile 
ﬂow was directed through the inner lumen and mimicked the na- 
tive cardiovascular environment with a constant ﬂow over time 
(2.5 ml/min). After 21, 42 and 63 days of culture, hiPSCs-derived 
ECs (1.0 ∗10 6 cells/cm 2 ) were seeded into the lumen of TEVGs from 
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both sides and rotated for 7 min to increase an evenly seeding. Af- 
terwards TEVGs were kept for additional 3 days under static cul- 
ture. The constructs were harvested after 24, 45 and 66 days of 
culture and immediately processed for immunohistochemistry and 
quantitative tissue analysis. 
2.6. Qualitative tissue analyses 
For immunohistochemical analysis of TEVGs, 5 μm sections de- 
rived from blocks of formalin-ﬁxed, paraﬃn-embedded tissue were 
mounted on glass slides (SuperFrost Plus, Menzel Gläser, Ger- 
many), deparaﬃnized, rehydrated and stained with hematoxylin 
and eosin (H&E), Masson Trichrome (MT) or Elastica van Gieson 
(EVG) using standard histological techniques. All sections were an- 
alyzed using a Mirax Midi BF slide scanner and processed using 
MIRAX viewer (Zeiss, Germany). In addition, immunoﬂuorescence 
for αSMA and vWF were performed by IHC-Service Lab, Univer- 
sity Hospital Zurich, Switzerland. Images were captured with a 
DM60 0 0B ﬂuorescence microscope (Leica, Germany) and processed 
using the Leica software (Leica, Germany). Furthermore, each sam- 
ple was analyzed using Image J software to determine the average 
wall thickness. 
2.7. Quantitative tissue analysis 
TEVGs (n = 4 per clone) were minced, lyophilized, and analyzed 
using biochemical assays for total deoxyribonucleic acid (DNA) 
content as an indicator for cell number, hydroxyproline (HYP) con- 
tent as an indicator for collagen, as well as for glycosaminoglycan 
(GAG) content. All samples were digested in papain (Sigma-Aldrich, 
Switzerland) solution (300 μg/mL in PBS with 5 mM EDTA) (Sigma- 
Aldrich, Switzerland) and 5 mM cysteine (Sigma-Aldrich, Switzer- 
land) at 65 °C for 16 h. For measuring the cellularity of the con- 
structs, the DNA amount was quantiﬁed according to manufac- 
turer’s protocol (Life Technologies, Switzerland, No. P11496). The 
GAG content was determined using a modiﬁed version of the pro- 
tocol described by Farndale et al. [22] , as previously described, and 
a standard curve prepared from chondroitin sulfate from shark car- 
tilage (Sigma-Aldrich, Switzerland). HYP was determined with a 
modiﬁed version of the protocol provided by Huszar et al. [23] . 
Remnants of the co-polymers matrices were visualized using po- 
larization microscopy. 
2.8. Statistical methods 
Quantitative data are presented as mean ± standard deviation. 
Quantitative tissue analysis were statistically evaluated using an 
unpaired students- t -test. P-values p < 0.05 were considered statisti- 
cally signiﬁcant ( ∗p < 0.05, ∗∗p < 0.03, ∗∗∗p < 0.001, ∗∗∗∗p < 0.0 0 01). 
Post-hoc correction was performed using the Bonferroni method 
where applicable. Kolmogorov-Smirnov normality test was used to 
conﬁrm that the datasets were normally distributed (p > 0.05). All 
statistical analyses were performed using the GraphPad Prism 5 
software (GraphPad Software Inc., USA). 
3. Results 
3.1. Characterization of human PBMCs derived iPSCs 
PBMCs were isolated from human peripheral blood using the 
Ficoll-Paque method. Reprogramming into hiPSCs was induced ac- 
cording to previously reported protocols [25] by simultaneous 
transduction of viral vectors containing OCT4, SOX2, c-MYC and 
KLF4. After about 30 days, embryonic stem-like colonies started to 
appear. Colonies displaying the characteristic morphology of hu- 
man ESCs ( Fig. 1 A) could be picked and expanded. These colonies 
showed high alkaline phosphatase (AP) activity ( Fig. 1 B) and ex- 
pressed the pluripotency associated transcription factors OCT4, 
SOX2, NANOG, REX1, and DPPA3 ( Fig. 1 C). All markers were upreg- 
ulated compared to the original, non-reprogrammed PBMCs, sug- 
gesting their transition to a pluripotent, undifferentiated state. Fur- 
thermore, the human speciﬁc pluripotency markers TRA-1-81 and 
TRA-1-60 ( Fig. 1 D and E) were also exclusively expressed in the 
hiPSC colonies. To assess the pluripotent potential of the generated 
hiPSCs, cells were ﬁrst differentiated in vitro into embryoid bod- 
ies (EBs). Analysis of the expression of early differentiation mark- 
ers revealed differentiation into all three germ layers: endoderm 
(FOXA2 and CXCR4), ectoderm (PAX6 and DCX) and mesoderm 
(MSX1 and PAX3) ( Fig. 1 F). In addition, hiPSCs were injected sub- 
cutaneously into NOD-SCID mice and teratomas were generated af- 
ter 10–12 weeks. Histological analyses revealed the presence of all 
three germ layers including ectoderm (neural epithelium), meso- 
derm (cartilage) and endoderm (intestinal epithelium) ( Fig. 1 G-I). 
Taken together, these results conﬁrmed the pluripotent nature of 
the generated hiPSCs. Three different clones were expanded and 
tested for the pluripotent status (Supplementary Fig. 1). Each as- 
say conﬁrmed the transition from peripheral blood cells into un- 
differentiated pluripotent cells for all clones. Furthermore, kary- 
otyping has been performed as an additional quality control and 
reprogrammed cell retained a normal karyotype (Supplementary 
Fig. 2). 
3.2. Characterization of human iPSC-derived smooth muscle and 
endothelial cells 
We next investigated the ability of three generated hiPSC 
clones (IREMi0 01A, IREMi0 01B, IREMi0 01C) to differentiate into 
SMCs and ECs, in order to use them for vascular TE applica- 
tions. Under muscle-inducing culture conditions, hiPSCs gradu- 
ally lost the expression of the pluripotency genes and gained 
the expression of the SMCs speciﬁc genes like αSMA, calponin 
and SMMHC ( Fig. 2 A and B). Interestingly, all hiPSC-derived SMC 
clones revealed positive expression of the smooth muscle myosin 
heavy chain (SMMHC) isotype SM2 (Supplementary Fig. 4). More- 
over, the hiPSC-derived SMCs showed a similar marker pro- 
ﬁle at RNA and protein level when compared to primary hu- 
man aortic SMCs ( Fig. 2 A and C, Supplementary Fig. 4). RT- 
PCR and immunostaining have been performed at day 21 and 
day 35 after differentiation start. To evaluate the differentiation 
eﬃciency ﬂow cytometric analysis for αSMA were performed 
and displayed 94.6–98.3% αSMA-positive cells (Supplementary 
Fig. 5). 
Similarly, hiPSC were also able to differentiate into ECs when 
cultured under speciﬁc conditions. RT-PCR and immunostaining 
have been performed at day 25 after differentiation start. Three 
different clones differentiated into ECs showed high expression of 
the ECs markers CD31, von Willebrand factor (vWF) and endoglin 
and concomitantly downregulation of the pluripotency markers 
OCT4, NANOG, and REX1 ( Fig. 2 C and D, Supplementary Fig. 6). 
Moreover, hiPSC-derived ECs expressed markers including CD31, 
vWF and endothelial nitric oxide synthase (eNOS) comparable to 
human umbilical cord vein-derived endothelial cells ( Fig. 2 C). The 
differentiation eﬃciency based on CD31 ﬂow cytometric analysis 
showed a variability between 52.7% and 84.2% (Supplementary Fig. 
7). In conclusion, the obtained hiPSC-derived SMCs and ECs did not 
show expression of any of the pluripotency markers by immunos- 
taining and PCR, and resembled native SMCs and ECs based on 
their characteristic markers. In total 3 clones were differentiated 
into SMCs or ECs. After differentiation, the three clones showed a 
similar expression proﬁle at RNA and protein level between each 
other (Supplementary Figs. 3 and 6). 
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Fig. 1. PBMC derived-iPSCs show the pluripotent nature of generated hiPSCs. A) Morphology of a hiPSC colony in culture. B) Alkaline phosphatase staining of cultured 
hiPSCs. C) Quantitative RT-PCR assay for expression analyses of pluripotency markers OCT4, SOX2, NANOG, REX1, and DPPA3 in hiPSCs. Data are normalized with GAPDH 
and relative to PBMCs. D-E) Immunostaining for pluripotency markers OCT4, SOX2, TRA-1-60 and TRA-1-81 in one representative iPSC clone. F) In vitro embryoid body (EB)- 
mediated differentiation of hiPSCs into three germ layers. Differentiated cells were analyzed by quantitative RT-PCR for the expression of endodermal (FOXA2 and CXCR4), 
ectodermal (PAX6 and DCX) and mesodermal (MSX1 and PAX3) lineage markers. Data are normalized with GAPDH and relative to undifferentiated hiPSCs. G-I) H&E staining 
of teratomas arising of immunodeﬁcient NSG mice. Teratoma containing neural tissues (ectoderm) (G), intestinal epithelium (endoderm) (H) and cartilage (mesoderm) (I). 
One representative clone is shown (IREMi001B). Quantitative data are presented as mean ± standard deviation. (Scale bars: 200 μm.) 
3.3. Qualitative and quantitative tissue analysis of TEVGs based on 
human iPSCs 
Human iPSC-derived SMCs and ECs were seeded onto a 
PGA/P4HB scaffold and cultured under static or dynamic condi- 
tions. Microstructural analysis using scanning electron microscopy 
(SEM) was used to analyze the ﬁber size and porosity of unseeded 
polymers before and after coating (Supplementary Fig. 8). Quanti- 
tative measurements of the ﬁber diameter and porosity (n = 4 per 
condition) were conducted. The ﬁber diameter was uniform among 
all biomaterials with no statistically signiﬁcant differences between 
the hybrid polymer or uncoated PGA. PGA-P4HB scaffolds were sig- 
niﬁcantly less porous than PGA (p < 0.05) (Supplementary Fig. 8f). 
After 3, 6 and 9 weeks the constructs were retrieved for histologi- 
cal analysis ( Fig. 4 ). Hematoxylin and Eosin (H&E) staining demon- 
strated formation of substantial amounts of extracellular matrix 
(ECM) in vitro and Masson Trichrome (MT) staining conﬁrmed de- 
position of collagen ﬁbers. Nevertheless, TEVGs under static con- 
ditions displayed high cellularity and layered tissue on the outer 
vessel regions, while in the central part of the scaffold low cellu- 
larity and no visible formation of ECM were present ( Fig. 3 , rows 
1, 3 and 5). In contrast, TEVGs under dynamic conditions exhib- 
ited high cellularity and tissue formation on the outer as well as 
on the inner vessel regions ( Fig. 3 , rows 2, 4 and 6). Nonethe- 
less, low cellularity was demonstrated between these two layers 
under static conditions compared to native controls after 3 weeks 
of culture. Generally, under dynamic culture the cells distributed 
homogenously within the scaffolds and displayed a better collage- 
nous ECM deposition on the outer as well as on the inner ves- 
sel regions in comparison to TEVGs under static conditions ( Fig. 3 ). 
In sum, vascular grafts cultured under dynamic conditions showed 
a better cellular inﬁltration and tissue formation in comparison 
to static culture. Furthermore, dynamically cultured TEVG (n = 4) 
show a signiﬁcant increase of wall thickness under dynamic con- 
ditions in comparison to statically cultured TEVG over culture time 
(p < 0.0 0 01, Supplementary Fig. 10). 
In order to quantify the composition of ECM, TEVGs were bio- 
chemically analyzed using assays for hydroxyproline (HYP), gly- 
cosaminoglycans (GAG), and the cell number (deoxyribonucleic 
acid, DNA) ( Fig. 4 A). These ﬁndings underlined the histological ob- 
servations showing cell proliferation and increasing ECM formation 
over the analyzed 9 weeks period. Moreover, TEVGs generated with 
the three hiPSC clones displayed similar amounts of HYP, GAG and 
DNA for the respective conditions with no detectable signiﬁcant 
differences, indicating lack of inter-individual differences (Supple- 
mentary Fig. 9). 
Overall dynamic conditions (n = 4) showed enhanced cell 
proliferation (p < 0.05) and signiﬁcant higher expression of GAG 
(p < 0.0 0 01), and HYP (p < 0.0 0 01) in comparison to static con- 
ditions after 9 weeks of culture. Interestingly, the amount of 
DNA (p < 0.0 0 01), GAG (p < 0.0 0 01), and HYP (p < 0.03) is also 
signiﬁcant higher between 3 weeks and 9 weeks under dynamic 
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Fig. 2. hiPSC-derived SMC and EC are comparable to primary cell sources. A) Quantitative RT-PCR assay for expression analyses of SMC markers αSMA, smoothelin, and 
calponin. Direct comparison between hiPSCs, hiPSC-derived SMCs and primary SMCs. B) Quantitative RT-PCR assay for the expression of OCT4, NANOG, and REX1 in hiP- 
SCderived SMCs and hiPSC. C) Quantitative RT-PCR assay for expression analyses of EC markers von Willebrand factor (vWF), endoglin and CD31. Direct comparison between 
hiPSCs, hiPSC-derived ECs and primary ECs. D) Quantitative RT-PCR assay for the expression of OCT4, NANOG, and REX1 in hiPSC-derived ECs and hiPSC. Data were nor- 
malized with GAPDH and relative to the undifferentiated hiPSCs. E) Direct comparison of immunostaining for undifferentiated hiPSCs, hiPSC-derived SMC, primary SMCs, 
hiPSC derived EC, and primary ECs. Following markers were tested: OCT4, alpha smooth muscle actin ( αSMA), calponin, smooth muscle myosin heavy chain (SMMHC), CD31, 
endothelial nitric oxide synthase (eNOS) and von Willebrand factor (vWF). One representative clone is shown (IREMi001B) and all experiments have been performed 2 times. 
Quantitative data are presented as mean ± standard deviation. (Scale bars: 100 μm.) 
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Fig. 3. Vascular grafts cultured under dynamic conditions showed abundant tissue formation. hiPSC-derived proliferative SMCs were seeded onto a PGA/P4HB scaffold and 
the constructs were cultured under static or dynamic conditions. The ﬁrst column shows macroscopic photos of TEVGs (n = 4 for each condition) after culture under both 
conditions. Next, hematoxylin and eosin (H&E) staining shows tissue formation. Masson’s trichrome staining (MT) displays collagenous extra cellular matrix formation after 
static and dynamic culture. The last column represents Elastica van Gieson (EVG). (Scale bars: 500 μm.) 
conditions. Polarization microscopy revealed the presence of initial 
scaffold matrix in the central part of the constructs ( Fig. 4 B). 
However, semi-quantitative analysis of dynamic constructs showed 
that the biomaterial remnants were signiﬁcant more degraded 
(p < 0.001) compared to static constructs after 9 weeks of culture. 
These ﬁndings additionally underline the histological observations 
previously described. The co-polymer starter matrices showed less 
remodeling and scaffold degradation in the central part of the 
constructs under static as well as dynamic conditions given the 
lack of tissue formation in this area of the constructs. 
3.4. Immunoﬂuorescence of TEVGs 
To determine the cellular phenotype in the TEVGs derived from 
hiPSCs, cells were stained for αSMA and vWF. Immunoﬂuores- 
cence staining of TEVGs under static as well as dynamic conditions 
demonstrated layered tissue architecture with an αSMA positive 
layer located in the interstitium and a thin luminal layer of vWF 
positive cells comparable to native vessels ( Fig. 5 ). After 3 weeks 
of culture the αSMA positive layer of TEVGs were thinner in com- 
parison to native tissue. The majority of cells stained positive for 
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Fig. 4. ECM formation increased and scaffold degraded during cultivation. A) Extracellular matrix analysis shows the amount of hydroxyproline (HYP), glycosaminoglycans 
(GAG), and the cell number (deoxyribonucleic acid, DNA) of TEVGs (n = 4 for each condition), which were statically or dynamically cultured up to 9 weeks. B) Polarization mi- 
croscopy revealed the presence of the initial scaffold matrix. Quantitative data are presented as mean ± standard deviation. ( ∗p < 0.05, ∗∗p < 0.03, ∗∗∗p < 0.001, ∗∗∗∗p < 0.0 0 01) 
(Scale bars: 500 μm.) 
αSMA were located at the outer layer of the statically cultured 
TEVGs. In contrast, dynamically cultured TEVGs showed a thicker 
αSMA positive layer ( Fig. 5 ). 
4. Discussion 
In vitro engineering of small diameter native-like vascular grafts 
is still demanding as poor haemocompatibility of TEVGs often 
leads to thrombosis and stenosis when implanted in vivo [5] . 
Therefore, creating a functional biomaterial that closely mimics the 
native layered architecture of blood vessels would represent a ma- 
jor step towards the functional replacement of diseased vascular 
structures. The current study is the ﬁrst report showing the possi- 
bility to employ human PBMC-derived iPSCs to generate synthetic 
scaffold-based TEVGs, which contained a αSMA-positive layer in 
the graft interstitium as well as a thin luminal layer of vWF- 
positive cells comparable to native vessels. Importantly, given the 
ease of access, this PBMC-based approach may open up the pos- 
sibility to generate native-like endothelialized ‘customized’ TEVGs 
to study complex human diseases in vitro not only enabling better 
understanding of the pathophysiology, but ultimately also allowing 
for assessment of novel therapeutic approaches in the future. 
Our data highlight the possibility to reprogram PBMCs into hiP- 
SCs and make use of these cells for engineering small diameter 
vascular grafts. The use of PBMCs has clear advantages over dermal 
ﬁbroblasts, which represent the most common source to generate 
hiPSCs [19,24] . For example, exposure of the dermis to ultraviolet 
(UV) light increases the risk for chromosomal aberrations [25] , fur- 
ther ﬁbroblast cells need to expand for several passages in vitro 
and make it a cumbersome cell source for reprogramming. In ad- 
dition, taking skin biopsies usually results in scar tissue formation 
and is less practical for non-therapeutic disease modeling settings 
or in volunteers. Beyond that, skin represents a non-reconstituting 
organ not providing unlimited supply to a certain donor tissue, im- 
plying that repetitive cell harvest seems more diﬃcult. In contrast, 
peripheral blood is a constantly reconstituting source of patient tis- 
sue that is not exposed to UV radiations. Moreover, it represents a 
low invasive and well-established cell source – a cell source one 
could use for large scale with repetitive isolation of sterile, viable, 
autologous, cellular material from patients as well as from volun- 
tary donors. 
Notwithstanding, direct reprogramming of somatic cells into 
cells of clinical value provides also a promising alternative strategy. 
The main advantages are (i) reduced time consumption, (ii) limited 
costs, and (iii) low risk for tumor formation. However, the repro- 
gramming eﬃciency and the limited scalability of this cell gener- 
ation system are the key challenges. In addition, the different cell 
types for direct reprogramming into SMCs and ECs in both mice 
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Fig. 5. TEVGs based on hiPSCs demonstrated layered tissue architecture. Immunohistological analyses of TEVGs (n = 3 for each condition) under static and dynamic conditions 
revealed positive expression of the smooth muscle cell marker alpha smooth muscle actin ( αSMA) in the interstitium and a thin luminal positive layer of endothelial cell 
marker von Willebrand factor (vWF). (Scale bars: 100 μm.) 
and humans are nowadays limited to ﬁbroblasts and amniotic ﬂuid 
derived cells [26] . 
Various reprogramming techniques have been established dur- 
ing the last years for generating hiPSCs [27] . So far, four main 
categories have been subdivided: integration-defective viral de- 
livery, episomal delivery, RNA delivery and protein delivery [27] . 
The original method of reprogramming murine ﬁbroblasts by Ya- 
manaka utilized retroviral transduction of Oct4, Sox2, Klf4, and 
c-Myc into MEF [19] . As lentiviruses, unlike retroviruses, can in- 
fect non-dividing and proliferating cells, this approach became the 
most preferred reprogramming procedure. 
In particular, for clinical applications reducing genomic modiﬁ- 
cations to prevent insertional mutagenesis is mandatory. Therefore, 
in order to obtain cells suitable for clinical application, transgene- 
free hiPSCs need to be employed to avoid transgene reactivation, 
altered gene expression and misguided differentiation. For this pur- 
pose, we and other laboratories studied the possibility of develop- 
ing more and more non-integrative or semi-integrative reprogram- 
ming approaches [28] . 
Another critical factor inﬂuencing the generation of TEVGs are 
the conditions in which they are cultured. We analyzed hiPSC- 
derived TEVGs cultured under static and dynamic conditions and 
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could demonstrated in the dynamic cultures increased cellularity, 
more tissue formation and scaffold degradation when compared to 
static culture, as conﬁrmed previously [29] . It has been shown that 
mechanobiological interactions between cells and scaffolds can 
crucially inﬂuence cell behavior [29,30] . Wang et al. also showed 
an enhanced cell proliferation under dynamic three-dimensional 
(3D) culture compared with conventional static two-dimensional 
(2D) and 3D cell culture conditions [31] . Niklason and colleagues 
investigated the effects of 8 weeks cyclic mechanical loading on 
tubular meshes of PGA seeded with adult bovine aortic smooth 
muscle cells placed around distensible silicone tubes [32] . The so- 
generated TE arteries were then implanted in miniature swine and 
showed a patency up to 24 days. 
The long-term patency of small-diameter vascular grafts is still 
a great challenge in the ﬁeld of cardiovascular TE research. Early 
luminal thrombosis represents the major cause of vessel occlu- 
sion. A possible solution represents the coating of the grafts with 
antithrombogenic materials, such as heparin [33] or ethylene ox- 
ide [34] , but the results still could not overcome the limitation 
completely. The vascular TE approach has been introduced to gen- 
erate vascular grafts with functional endothelium potentially en- 
abling long-term patency [35] . This project showed the production 
of hiPSC-derived TEVGs, which contained a αSMA-positive layer 
in the interstitium and a thin luminal layer of vWF-positive cells 
comparable to native vessels. This underlines the impact of a func- 
tional endothelial cell layer in TEVGs. Future effort s will f ocus on 
the implantation of our TEVGs also to investigate the in vivo func- 
tionality and patency of human PBMC-iPSC-based TEVGs compared 
to mature vascular cell-derived constructs. 
In the past, murine [36] and hiPSCs [37] were differentiated 
into SMCs and used to construct a TEVG for subcutaneous im- 
plantation for 2 weeks. Furthermore, Gui et al. implanted a hiPSC- 
derived TEVG into nude rats as abdominal aorta interposition for 
2 weeks [38] . These TEVG contained αSMA and SMMHC-positive 
cells. Nevertheless, they also observed thrombus formation in some 
samples, possibly due to the lack of endothelial cell coating of vas- 
cular grafts before implantation [32] . So far, these studies have 
been based on the reprogramming of human ﬁbroblasts. Recently, 
Hu et al. established integration-free reprogrammed hiPSCs from 
PBMCs and then differentiated the cells into mesoderm-originated 
cardiovascular progenitor cells (CVPCs) [39] . Subcutaneous implan- 
tation of CVPCs seeded on a disc shaped scaffold led to in vivo lin- 
eage speciﬁcation [39] . However, no fully autologous TEVG based 
on SMCs and endothelial cells (ECs) differentiated from PBMC- 
derived hiPSC based on a fully biodegradable scaffold system has 
been realized so far. Our data demonstrates for the ﬁrst time the 
feasibility to use pre-differentiated human ECs and SMCs differen- 
tiated from PBMC-derived hiPSCs for the production of bioengi- 
neered blood vessels with architecture comparable to native ves- 
sels. 
5. Conclusion 
Human iPSCs generated from PBMCs is a promising cell source 
for TE as they are easily accessible and may thus serve as a versa- 
tile platform also involving disease-modeling applications. In addi- 
tion to solving ethical concerns related to the use of blastocyst- 
derived ESCs, the use of hiPSCs for the generation of therapeu- 
tic cells may avoid the necessity for post-transplant immunosup- 
pression. Upon appropriate differentiation, these cells can then be 
used to study normal and pathologic human tissue development in 
vitro, enabling new insights into disease pathology as well as the 
development of novel therapeutic agents and patient-speciﬁc cel- 
lularized replacements. In summary, our study established an eﬃ- 
cient approach towards generating patient-speciﬁc small diameter 
TEVGs based on human PBMC-iPSC-derived SMCs and ECs, contain- 
ing native-like layered vessel architecture. 
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